Bactolife
PrivateLast Round
Series B
Jan 6, 2026
Est. Valuation
$23.26M
Total Funding Raised
$81.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Bactolife operates in Healthcare & Life Sciences and is based in Copenhagen. Its latest recorded funding round was a Series B round in January 2026.
Bactolife is a biotechnology company that develops proprietary Binding Protein ingredients designed to fortify the gut microbiome and reduce the risk of gastrointestinal infections in humans and animals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bactolife Comparables
Compare Bactolife with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ginkgo Bioworks | 71% | |
| Symrise AG | 63% | |
| Cargill | 60% |
For institutional investors. Book with your work email.
Bactolife Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 6, 2026 | ||||
| Series A | Aug 8, 2023 | ||||
| Grant | Aug 30, 2022 | ||||
| Seed | Apr 19, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Bactolife Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Selfinvest | Seed, Series A |
| Athos KG | Series B, Series A |
| Gates Family Foundation | Series B |
| Gates Foundation | Series B, Grant, Series A |
| Novo Holdings | Series B, Series A, Seed |
| The Bill & Melinda Gates Foundation Trust | Grant, Series A |
| Novoseeds | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 140% MoM, reaching 1.7K.
- Feb 24, 2026
Binding Proteins product to target mass market from 2027.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 28, 2026
At SupplySide Global in Nevada on Oct 28th–30th '26, Bactolife showcases its Helm(TM) Binding Protein technology in Expo Hall, Exhibit #2172, and connects with food, beverage, nutrition, and dietary supplement industry leaders.
For institutional investors. Book with your work email.
Bactolife Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Bactolife's valuation, stock price, and market status.
Is Bactolife a public or private company?
Bactolife is a private company.
What is the current stock price of Bactolife?
Bactolife is a private company, so its shares have no public market price. Caplight tracks Bactolife's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bactolife worth (valuation)?
Bactolife's valuation is estimated at $23.3M based on funding round data.
Can I buy Bactolife stock?
Bactolife shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bactolife's last funding round?
Bactolife's most recent funding round was Series B on January 6, 2026.
Who are the main investors in Bactolife?
Key investors in Bactolife include Athos KG, Novo Holdings, Novoseeds, Cross Border Impact Ventures, The Export and Investment Fund of Denmark.
Will Bactolife IPO soon?
No public IPO plans have been announced for Bactolife.
How can I track Bactolife secondary market activity?
Caplight tracks bids, offers, and trades in Bactolife's shares on secondary markets.